In the BioHarmony Drug Report Database
Lisocabtagene maraleucel
Breyanzi (lisocabtagene maraleucel) is a gene pharmaceutical. Lisocabtagene maraleucel was first approved as Breyanzi on 2021-02-05. It is used to treat b-cell lymphoma in the USA.
Trade Name
|
Breyanzi |
|---|---|
Common Name
|
lisocabtagene maraleucel |
ChEMBL ID
|
CHEMBL4297236 |
Indication
|
b-cell lymphoma |
Drug Class
|
Antineoplastic |
Image (chem structure or protein)
